Pharnext

Edison Investment Research is terminating coverage on Pharnext (ALPHA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Equities

Equities by Sector

Sectors

Thematics

Latest

Why is gold hitting new highs?

Saba Capital campaign – Your vote matters

Market outlook: What lies ahead in 2025

Audiovisual

Latest

Webinar – Saba Capital’s impact on the UK investment trusts industry

Deutsche Beteiligungs in 60 seconds

Uncovering Trusts – Saba Capital Campaign

About Edison

About Edison

Careers

Pharnext (PAR: ALPHA)

Latest Insights

Pharnext — Potential licensing deals could add confidence

Pharnext — Improving FY23 financial footing

Pharnext — Revised legal structure to offer operational stability

Pharnext — Neovacs trust to manage Pharnext deal

Sector

Research

Pharnext — Approaching clinical validation

Pharnext — €12m loan to ease funding overhang

Pharnext — Neovacs €2.5m loan part of a potential larger deal

Pharnext — PREMIER trial completes patient recruitment

Pharnext — Convertible debt terms revised

Pharnext — Clinically healthy

Pharnext — Back in the saddle again

Pharnext — Pivotal Phase III initiated

Pharnext — R&D day highlights

Pharnext – executive interview

Pharnext — New efficacy and new indications from old drugs

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time